Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Evotec is a drug discovery and development partner that helps pharmaceutical and biotech companies turn early scientific ideas into candidate medicines.
Evotec is a behind-the-scenes drug hunter. Big pharmaceutical companies and small biotech startups hand it their hardest early-stage problems — find a molecule that hits a disease target, test whether it is safe, figure out how to manufacture it — and Evotec does the lab work and thinking to move a project from a raw idea toward something that can be tested in people.

The business runs on partnerships rather than selling a single product. Customers pay for research services and for longer, shared-risk deals where Evotec puts in its own expertise and sometimes its own money in exchange for milestone payments or a cut of future royalties if a drug succeeds. That second model is the interesting bet: it makes Evotec less like a hired lab and more like a part-owner of other companies' pipelines, sharing the upside if a medicine makes it to market. Its headquarters in Hamburg, Germany, sits at the center of a wide network of science sites across Europe and the United States. The industry it lives in is brutally competitive and science-heavy. Rivals range from large contract research organizations to specialized discovery shops, and the big drugmakers it serves constantly reshuffle their research budgets. Evotec's edge is depth — years of accumulated know-how in specific disease areas and technology platforms, plus scale that a tiny biotech cannot match. Its vulnerability is the same coin: when biotech funding dries up or pharma companies cut back on early research, demand for its services can cool quickly.
The company has grown largely by buying up capabilities and scientific teams rather than building everything itself, and it spends heavily on its own technology platforms to stay ahead. Like many research-heavy businesses, profits are thin and lumpy relative to revenue, so the real test is whether its shared-risk bets eventually pay off in royalties. It is a company whose fate rides on other people's drugs succeeding — a quiet but essential cog in how new medicines actually get made.
Saved answer · last researched 16 Nov 2026